Valeant Pharmaceuticals International
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Valeant Pharmaceuticals International's revenues will increase 27.3% and EPS will grow 9.6%.
The average estimate for revenue is $1.09 billion. On the bottom line, the average EPS estimate is $1.25.
Last quarter, Valeant Pharmaceuticals International notched revenue of $986.3 million. GAAP reported sales were 43% higher than the prior-year quarter's $688.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.22. GAAP EPS were -$0.29 for Q4 versus $0.17 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 78.9%, 290 basis points worse than the prior-year quarter. Operating margin was 31.9%, 180 basis points worse than the prior-year quarter. Net margin was -9.0%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $4.61 billion. The average EPS estimate is $5.60.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 197 members out of 223 rating the stock outperform, and 26 members rating it underperform. Among 76 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 69 give Valeant Pharmaceuticals International a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Valeant Pharmaceuticals International is outperform, with an average price target of $69.88.
- Add Valeant Pharmaceuticals International to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Valeant Pharmaceuticals' Stellar 43% Gain in 2017, Explained
Wall Street rewards the embattled Valeant after the company met numerous goals last year.
3 Compelling Reasons Valeant Pharmaceuticals Exploded Higher by 24% in December
Valeant took another step forward on its road to redemption, but it still has a long walk ahead.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.